EFFECT OF BIVALIRUDIN VERSUS UNFRACTIONATED HEPARIN IN TRANSCATHETER AORTIC VALVE REPLACEMENT WITH SELF-EXPANDING VALVES: FROM THE BRAVO-3 RANDOMIZED TRIAL

Jaya Chandrasekhar,Axel Linke,Christian Hengstenberg,Serdar Farhan,Christophe Tron,Andreas Fach,Stephan Windecker,Raban Jeger,Gennaro Sardella,John Webb,Ulrich Schäfer,Thierry Lefèvre,Christian Kupatt,D. Tchetche,Nicolas Dumonteil,Antonio Colombo,Efthymios Deliargyris,Usman Baber,Roxana Mehran,Prodromos Anthopoulos,George Dangas

EFFECT OF BIVALIRUDIN VERSUS UNFRACTIONATED HEPARIN IN TRANSCATHETER AORTIC VALVE REPLACEMENT WITH SELF-EXPANDING VALVES: FROM THE BRAVO-3 RANDOMIZED TRIAL

2017

Background: Selection of valve and sheath type may impact on procedural complications in transcatheter aortic valve replacement (TAVR). Whether bivalirudin (BIV) reduces bleeding compared with unfractionated heparin (UFH) specifically with self-expanding (SE) TAVR is unknown. We sought to compare

Keywords:

Heparin
Randomized controlled trial
Aortic valve replacement
Internal medicine
Bivalirudin
Cardiology
Medicine
transcatheter aortic
Valve replacement

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations